phase II clinical study
Pharming Group Launches Phase II Trial of Leniolisib in Multiple Primary Immunodeficiencies
The firm is evaluating leniolisib, which is already approved and sold under the brand name Joenja for APDS, in certain primary immunodeficiencies with immune dysregulation.
Carrick Therapeutics Advances Second CDK Inhibitor Into Clinic, Explores Biomarker Approaches
Premium
The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026.
Aurigene Oncology Advancing BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma Trial
After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.
Pierre Fabre, Scorpion Therapeutics Begin Phase I/II Trial in 'Double-Mutant' NSCLC Patients
The partners are studying a drug designed to target EGFR exon 19 or exon 21 mutations with a co-occurring C797S mutation.
The radiopharmaceutical, already approved for SSRT-expressing GEP-NETs, may be a new option in meningioma if future research validates findings from this small study.